<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04318847</url>
  </required_header>
  <id_info>
    <org_study_id>OND-URG</org_study_id>
    <nct_id>NCT04318847</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial</brief_title>
  <official_title>Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lizar Aguirre Pascasio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basque Health Service</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is intended to evaluate the efficacy and safety of the administration of&#xD;
      ondansetron in children with mild-moderate dehydration.&#xD;
&#xD;
      The target population will be children between 4 and 13 years old who present vomiting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 10, 2021</start_date>
  <completion_date type="Anticipated">April 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of children who return to medical/pediatric consultation for de same episode</measure>
    <time_frame>An average of 24 months</time_frame>
    <description>Is calculated percentage of children who return to medical/pediatric consultation for de same episode of vomiting</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Vomiting in Infants and/or Children</condition>
  <arm_group>
    <arm_group_label>Ondransetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of ondansetron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual Clinical Practice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Habitual Clinical Practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 MG</intervention_name>
    <description>Administration of ondansetron 4 mg or 8 mg according to weight</description>
    <arm_group_label>Ondransetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of at least 2 vomits in the last 4 hours.&#xD;
&#xD;
          -  Negative tolerance test.&#xD;
&#xD;
          -  Signature of the informed consent by the parents or legal guardians.&#xD;
&#xD;
          -  Diagnosis of vomiting or diagnosis of acute gastroenteritis with vomiting.&#xD;
&#xD;
          -  Patients weighing 15 kg or more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Altered conciousness.&#xD;
&#xD;
          -  Sospected acute abdomen (appendicitis, invaginations...).&#xD;
&#xD;
          -  Suspicion or presence of obstructive disease.&#xD;
&#xD;
          -  Known severe digestive disease (ChronÂ´s disease, ulcerative colitis...).&#xD;
&#xD;
          -  Suspected food poisoning.&#xD;
&#xD;
          -  Allergy to any of the drugs used in the study.&#xD;
&#xD;
          -  Severe dehydration.&#xD;
&#xD;
          -  Bilious vomiting.&#xD;
&#xD;
          -  Previous abdominal surgery.&#xD;
&#xD;
          -  Pathology that may affective degree of hydration of the patient (kidney failure,&#xD;
             hypoalbuminemia..).&#xD;
&#xD;
          -  Admission requirement or intravenous rehydration for any reason.&#xD;
&#xD;
          -  Concomitant use of apomorphine.&#xD;
&#xD;
          -  In relation to the possible lengthening of the QT, patients with problems of previous&#xD;
             arrhythmia should be excluded or that they are receiving concomitant medication that&#xD;
             can lengthen the QT, that have electrolyte disturbances.&#xD;
&#xD;
          -  Patients receiving other serotonergic drugs.&#xD;
&#xD;
          -  Patients who have undergone a previous adenotonsillectomy.&#xD;
&#xD;
          -  Patients with hypocalcemia and/or hypomagnesemia.&#xD;
&#xD;
          -  Patients with hereditary fructose intolerance.&#xD;
&#xD;
          -  Diabetes patients.&#xD;
&#xD;
          -  Lactose intolerant patients.&#xD;
&#xD;
          -  Patients with indication of the low sodium diets.&#xD;
&#xD;
          -  Hypersensitivity to ondansetron or other antagonists of the 5-HT3.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lizar Aguirre Pascasio, Dr</last_name>
    <phone>945007374</phone>
    <email>LIZAR.AGUIRREPASCASIO@osakidetza.eus</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Basque Health Service</investigator_affiliation>
    <investigator_full_name>Lizar Aguirre Pascasio</investigator_full_name>
    <investigator_title>Doctor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dehydration</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

